CTMX · CytomX Therapeutics, Inc. · Webcasts, Transcripts & Audio
$2.04
+0.00 (+0.00%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$444.73M
Shares
218.00M
Volume · Nov 13
2.72M
Avg daily vol (3M)
4.16M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
CytomX Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for CytomX Therapeutics, Inc. (CTMX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-18
CytomX Therapeutics, Inc. (CTMX) November 18, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-09
CytomX Therapeutics, Inc. (CTMX) November 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-05
CytomX Therapeutics, Inc. (CTMX) Q3 2026 Earnings Call Transcript
Confident tone
Varsetta M registrational development
Combination development in earlier-line colorectal cancer
Varsetta M safety and dose optimization
Revenue
$1.69M
▼ 71.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
CytomX Therapeutics, Inc. (CTMX) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-08
CytomX Therapeutics, Inc. (CTMX) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
Confident tone
Varsetta M monotherapy in late-line CRC
Pan-tumor / GI expansion cohorts
Registrational study planning and timelines
Revenue
$1.42M
▼ 92.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-06-17
CytomX Therapeutics, Inc. (CTMX) June 17, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-10
CytomX Therapeutics, Inc. (CTMX) June 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-04
CytomX Therapeutics, Inc. (CTMX) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
Confident tone
Varsetta M (VarsettaM) in colorectal cancer
Dose optimization and registrational path
EPCAM targeting and ProBody platform
Revenue
$10.26M
▼ 79.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-16
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
Confident tone
Varsetta Phase 1 dose expansion efficacy in CRC
Dose optimization cohorts (8.6 / 10 mg/kg, AIBW dosing)
EPCAM ProBody platform and Mazatecan payload
Revenue
$663,000*
▼ 98.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript
Confident tone
CX-2051 Phase I data and progress in colorectal cancer
PROBODY platform and EpCAM targeting
CX-801 masked interferon alpha-2b in melanoma
Revenue
$5.96M
▼ 82.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript
Confident tone
CX2051 in colorectal cancer
CX801 / Keytruda combination in melanoma
Safety and tolerability, especially diarrhea
Revenue
$18.66M
▼ 25.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
CytomX Therapeutics, Inc. (CTMX) Q1 2025 Earnings Call
Revenue
$50.92M
▲ 22.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript
Positive tone
CX-2051 lead EPCAM ADC in colorectal cancer
CX-801 masked interferon alpha program
Unmet need and bar for activity in late-line CRC
Revenue
$38.09M*
▲ 43.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call
Revenue
$33.43M
▲ 26.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
CytomX Therapeutics, Inc. (CTMX) Q2 2024 Earnings Call Transcript
Confident tone
CX-904 EGFR-CD3 PROBODY T-cell Engager
CX-2051 EpCAM PROBODY ADC
Amgen partnership and Phase 1b strategy
Revenue
$25.11M
▲ 1.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
CytomX Therapeutics, Inc. (CTMX) Q1 2024 Earnings Call Transcript
Confident tone
CX-904 Phase Ia dose escalation data
Safety profile and therapeutic window
Dose optimization and step dosing strategy
Revenue
$41.46M
▲ 76.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-11
CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript
Positive tone
CX-904 EGFRxCD3 Probody T-cell engager
Upcoming pipeline milestones / catalysts
CX-2051 EpCAM Probody ADC
Revenue
$26.61M*
▲ 32.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Call Transcript
Revenue
$26.38M
▲ 136.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript
Revenue
$24.72M
▲ 92.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript
Revenue
$23.50M
▲ 159.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-27
CytomX Therapeutics, Inc. (CTMX) Q4 2022 Earnings Call Transcript
Revenue
$20.12M*
▲ 80.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
CytomX Therapeutics, Inc. (CTMX) Q3 2022 Earnings Call Transcript
Revenue
$11.15M
▼ 36.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
CytomX Therapeutics, Inc. (CTMX) Q2 2022 Earnings Call Transcript
Revenue
$12.85M
▼ 21.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
CytomX Therapeutics, Inc. (CTMX) Q1 2022 Earnings Call Transcript
Revenue
$9.04M
▼ 43.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
CytomX Therapeutics, Inc. (CTMX) Q4 2021 Earnings Call Transcript
Revenue
$11.13M
▲ 57.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
CytomX Therapeutics, Inc. (CTMX) Q3 2021 Earnings Call Transcript
Revenue
$17.59M
▼ 1.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
CytomX Therapeutics, Inc. (CTMX) Q2 2021 Earnings Call Transcript
Revenue
$16.29M
▼ 1.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
CytomX Therapeutics, Inc. (CTMX) Q1 2021 Earnings Call Transcript
Revenue
$15.97M
▼ 67.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-19
CytomX Therapeutics, Inc. (CTMX) Q4 2020 Earnings Call Transcript
Revenue
$7.08M
▼ 14.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
CytomX Therapeutics, Inc. (CTMX) Q3 2020 Earnings Call Transcript
Revenue
$17.79M
▲ 66.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
CytomX Therapeutics, Inc. (CTMX) Q2 2020 Earnings Call Transcript
Revenue
$16.61M
▲ 84.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
CytomX Therapeutics, Inc. (CTMX) Q1 2020 Earnings Call Transcript
Revenue
$49.59M
▲ 68.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
CytomX Therapeutics, Inc. (CTMX) Q4 2019 Earnings Call
Revenue
$8.28M
▼ 27.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–35 of 35 webcasts
Key facts
CIK
1501989
CUSIP
23284F105
13F (30d)
139 filings
124 filers
Visit website
Investor relations